来源:药渡撰文:Pharmadeep编辑:维他命2025年10月30日, NMPA官网显示,正式批准乐普生物自主研发的维贝柯妥塔单抗(MRG003)上市,用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌成人患者。该药物不仅是国内首个获批的EGFR靶向抗体偶联药物(ADC),更是全球范围内临床研究进度领先的创新疗法,标志着我国在ADC药物研发领域实现重大突破。图...
Source Link来源:药渡撰文:Pharmadeep编辑:维他命2025年10月30日, NMPA官网显示,正式批准乐普生物自主研发的维贝柯妥塔单抗(MRG003)上市,用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌成人患者。该药物不仅是国内首个获批的EGFR靶向抗体偶联药物(ADC),更是全球范围内临床研究进度领先的创新疗法,标志着我国在ADC药物研发领域实现重大突破。图...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.